Clinical Research, Pharma & Healthcare Financing

Cutera Completes Restructuring, Strengthens Capital Structure

CUTERA

Emerges from Chapter 11 as a stronger company, well positioned for long-term growth

Continuing to provide best-in-class aesthetic and dermatology solutions to customers

CUTERA, INC., (“Cutera” or “the Company”), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11.

Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders.

“Today marks a significant milestone for Cutera, as we strengthen the foundation we’ve built for over 25 years, so that we can serve the medical aesthetics industry in even greater ways in the years to come,” said Taylor Harris, CEO of Cutera. “With an enhanced capital structure and the support and confidence of our new owners, we are better positioned than ever to advance our growth strategy, drive innovation, and deliver industry-leading solutions and support to our customers all around the globe. We are incredibly grateful to our employees for their dedication, to our customers and partners for their loyalty, and to our new owners for their partnership in building a global powerhouse in aesthetics and dermatology.”

In connection with emergence, Cutera will operate as a private company, backed by a consortium of leading investment firms.

Advisors

Cutera is advised in this matter by Ropes & Gray LLP and Hunton Andrews Kurth LLP as legal counsel, Houlihan Lokey as investment banker, and FTI Consulting as financial advisor. The group of the Company’s lenders is advised in this matter by Paul, Weiss, Rifkind, Wharton & Garrison LLP as legal counsel and Centerview Partners as investment banker.

Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!

Related posts

Caris Life Sciences Raises $168M to Expand Precision Platform

PR Newswire

AN2 Therapeutics Shares Phase 3 EBO-301 Data and Future Milestones

Business Wire

Palleon Announces NMPA IND Clearance for Phase 2 Trial of E-602

Business Wire